Remarkably, bilateral gene therapy carried out as late as P30 led to significant utricular recovery in Ush1g–/– mice, suggesting that the time window for gene therapy is broader for vestibular deficits linked to USH1G than for the associated deafness. This evidence concerns the gene USH1G and deafness.